LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
LENZ Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
LENZ Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.79M, down 86.1% year over year. For fiscal 2025 it was $18.67M, down 37.4% from the year before. The highest annual figure on record is $72.79M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67M | -37.4% |
| FY2024 | Dec 31, 2024 | $29.80M | -49.9% |
| FY2023 | Dec 31, 2023 | $59.50M | -18.2% |
| FY2022 | Dec 31, 2022 | $72.79M | +91.9% |
| FY2021 | Dec 31, 2021 | $37.93M | +315.8% |
| FY2020 | Dec 31, 2020 | $9.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $3.79M | -41.2% |
| Q2 FY2025 | Jun 30, 2025 | $9.06M | +30.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.82M | -44.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.87M | -70.0% |
| Q3 FY2024 | Sep 30, 2024 | $6.45M | -62.1% |
| Q2 FY2024 | Jun 30, 2024 | $6.95M | -45.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.54M | +2.1% |
| Q4 FY2023 | Dec 31, 2023 | $19.54M | +5.8% |
| Q3 FY2023 | Sep 30, 2023 | $17.00M | -7.1% |
| Q2 FY2023 | Jun 30, 2023 | $12.64M | -28.9% |
| Q1 FY2023 | Mar 31, 2023 | $10.33M | -43.4% |
| Q4 FY2022 | Dec 31, 2022 | $18.46M | +64.8% |
| Q3 FY2022 | Sep 30, 2022 | $18.30M | +110.8% |
| Q2 FY2022 | Jun 30, 2022 | $17.78M | +40.3% |
| Q1 FY2022 | Mar 31, 2022 | $18.25M | +239.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.21M | +75.4% |
| Q3 FY2021 | Sep 30, 2021 | $8.68M | +275.9% |
| Q2 FY2021 | Jun 30, 2021 | $12.67M | +2894.6% |
| Q1 FY2021 | Mar 31, 2021 | $5.38M | – |
| Q4 FY2020 | Dec 31, 2020 | $6.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.31M | – |
| Q2 FY2020 | Jun 30, 2020 | $423.00K | – |
See a number that looks wrong?